Oral Isotretinoin for Photoaging: Results of a Randomized Controlled Phase II Trial
Primary Purpose
Photoaging, Epidermal p53 Expression
Status
Completed
Phase
Phase 2
Locations
Brazil
Study Type
Interventional
Intervention
oral isotretinoin and Mexoryl SX / XL
Mexoryl XL / SX
Sponsored by
About this trial
This is an interventional treatment trial for Photoaging focused on measuring photoaging, isotretinoin, profilometry, digital analysis
Eligibility Criteria
Inclusion Criteria:
- menopausal or sterilized women
Exclusion Criteria:
- woman at risk of pregnancy, with alterations on liver function or lipid profile
Sites / Locations
- Federal University of Sao Paulo
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
A
B
Arm Description
A - 21 subjects were treated 20mg isotretinoin 3/week plus moisturizer and sunscreen,for three months; 10 randomly selected were submitted to skin biopsies before and after the end of treatment
11 subjects received only the same moisturizer/sunscreen
Outcomes
Primary Outcome Measures
histological findings
Secondary Outcome Measures
laboratory tests
Full Information
NCT ID
NCT00701740
First Posted
June 18, 2008
Last Updated
August 13, 2018
Sponsor
Federal University of São Paulo
1. Study Identification
Unique Protocol Identification Number
NCT00701740
Brief Title
Oral Isotretinoin for Photoaging: Results of a Randomized Controlled Phase II Trial
Official Title
Phase II Randomized Controlled Trial to Evaluate the Clinical and Histological Effects of Oral Isotretinoin for the Treatment of Photoaging on Face and Forearms
Study Type
Interventional
2. Study Status
Record Verification Date
August 2018
Overall Recruitment Status
Completed
Study Start Date
July 2007 (undefined)
Primary Completion Date
January 2008 (Actual)
Study Completion Date
June 2008 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Federal University of São Paulo
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
A clinical and histological randomized controlled phase II trial to evaluate the efficacy and safety of oral isotretinoin for treating photoaging was performed with 32 menopausal or sterilized women aged 40-55y. The subjects were included in two randomly selected groups: A- 21 women received 20mg oral isotretinoin 3x week, moisturizer, sunscreen SPF 60 during three months; B- 11 women received only same moisturizer/sunscreen.
Detailed Description
Clinical assessment ranging from -2=very bad to +2=very good for all patients. Also, profilometry, corneometer and skin elasticity tests in periocular regions and left forearm; skin biopsy on left forearm before/after treatment in B and in 10 randomly selected patients from A. Microscopic evaluation of corneal layer and epidermal thickness, dermal elastosis, new collagen and p53 epidermal expression performed by quantitative digital image analysis. Blind evaluations (group/time) conducted by two independent observers.
Clinical evaluation results showed no alterations (0) or slight improvement (+1) for all patients; profilometry, corneometer and skin elasticity measurements presented a significant difference in pre and post treatment values (p=0,001 to 0,028) with no differences between A/B. Regarding histological findings and p53 expression no previous differences between groups before the treatment were observed (p>0,1).Quantitative microscopic digital analysis demonstrated no differences between groups at the end of the study for the majority of variables. However, slight but significant difference between A/B subjects was found for p53 with major expression reduction for those treated with oral isotretinoin [0,66±0,31 vs 0,94±0,34 respectively (p=0,04)]. The main side effects were cheilitis in 15 patients (75%) and xerophthalmia in 5 (25%). No significant alterations occurred in biochemical tests.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Photoaging, Epidermal p53 Expression
Keywords
photoaging, isotretinoin, profilometry, digital analysis
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
32 (Actual)
8. Arms, Groups, and Interventions
Arm Title
A
Arm Type
Active Comparator
Arm Description
A - 21 subjects were treated 20mg isotretinoin 3/week plus moisturizer and sunscreen,for three months; 10 randomly selected were submitted to skin biopsies before and after the end of treatment
Arm Title
B
Arm Type
Active Comparator
Arm Description
11 subjects received only the same moisturizer/sunscreen
Intervention Type
Drug
Intervention Name(s)
oral isotretinoin and Mexoryl SX / XL
Other Intervention Name(s)
isotretinoin, mexoryl
Intervention Description
20mg, 3/week,continuously for three months
Intervention Type
Drug
Intervention Name(s)
Mexoryl XL / SX
Other Intervention Name(s)
mexoryl
Intervention Description
11 subjects used only the same moisturizer and SPF 60 sunscreen
Primary Outcome Measure Information:
Title
histological findings
Time Frame
before and after 3 months
Secondary Outcome Measure Information:
Title
laboratory tests
Time Frame
before, after 1 and 3 months
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
menopausal or sterilized women
Exclusion Criteria:
woman at risk of pregnancy, with alterations on liver function or lipid profile
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Edileia Bagatin, MD, PHD
Organizational Affiliation
Federal University of Sao Paulo
Official's Role
Principal Investigator
Facility Information:
Facility Name
Federal University of Sao Paulo
City
Sao Paulo
State/Province
SP
ZIP/Postal Code
04023-900
Country
Brazil
12. IPD Sharing Statement
Learn more about this trial
Oral Isotretinoin for Photoaging: Results of a Randomized Controlled Phase II Trial
We'll reach out to this number within 24 hrs